Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29976363 | 1.00 | ADRB2 (0.48) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL5742922 | 0.89 | CYP2D6 (0.50) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL11606505 | 0.86 | TSHR (0.50) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL477602 | 0.85 | ACP3 (0.53) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL477580 | 0.85 | ACP3 (0.53) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL29609159 | 0.85 | ACP3 (0.53) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL6918732 | 0.83 | ADRB2 (0.48) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL11719059 | 0.83 | ADRB2 (0.42) | ADRB2ADRB1AOC3HIF1ACYP2D6 | |
| SCHEMBL30986710 | 0.82 | TSHR (0.58) | ADRB2ADRB1AOC3TSHRLMNA | |
| SCHEMBL4082510 | 0.82 | TSHR (0.58) | ADRB2ADRB1AOC3TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333985-B1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240262814-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4333985-A1 | MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117561251-A | Modulators of TREX1 | 星座制药公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2022235725-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-111393705-B | Hydrophilic molecularly imprinted resin and preparation method and application thereof | 河北大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-111393705-A | Hydrophilic molecularly imprinted resin and preparation method and application thereof | 河北大学 | 2020-07-10 | — | — | CN | disclosed |
| US-8440690-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8404712-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-26 | — | — | US | disclosed |
| EP-2313404-B1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2007053435-A1 | 3 -MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007050719-A1 | 8-[BIS-(2-CHLORO-PHENYL)-METHYL]-3-PHENYL-8-AZA-BICYCLO [3.2.1] OCTANE-3-CARBOXYLIC ACID AMIDE AS LIGAND FOR THE NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
| WO-2006031788-A2 | PROCESS FOR PREPARING SUBSTITUTED 8-AZABICYCLO[3.2.1] OCTAN-3-OLS | SCHERING-PLOUGH LTD. (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058343-A1 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2006-03-16 | — | — | US | disclosed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1618105-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004096794-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-0124287-A2 | Method and test composition for determination of hydrogen peroxide | Kyowa Medex Co. Ltd. (JP) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | ADRB2 131/4885ADRB1 116/4885AOC3 413/4885 |
| US-20240262814-A1 | MODULATORS OF TREX1 | CFTR, SLC10A1, CYP27A1 | ADRB2 2819/4885ADRB1 1727/4885AOC3 3523/4885 |
| US-20060058343-A1 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | ODC1, CYP2C8, OR10J3 | ADRB2 1181/4885ADRB1 1587/4885AOC3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.